Syncom Formulations (India) Ltd
NSE:SYNCOMF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Syncom Formulations (India) Ltd
Total Equity
Syncom Formulations (India) Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Syncom Formulations (India) Ltd
NSE:SYNCOMF
|
Total Equity
₹3.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Equity
₹360.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Equity
₹329.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Equity
₹778.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Total Equity
₹196.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Equity
₹84.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
Syncom Formulations (India) Ltd
Glance View
Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh. The firm manufactures and markets more than 300 pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquid orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments and inhalers. Its segments include Pharmaceuticals Drugs & Formulations, Trading of Commodities and Renting of property. Its product categories include tablets, capsules, ointments, injections, liquid-oral and packaging variants. The company offers various products, including generics, alpha adrenoceptor agonist, analgesic, antipyretic, anti-inflammatory, anti-ulcer agents, antibiotic, antidepressant, antiviral, cephelo sporins, cortico steroid, estrogen, cough suppressant and sedative anticonvulsant, among others. The firm operates in more than 15 countries across the world.
See Also
What is Syncom Formulations (India) Ltd's Total Equity?
Total Equity
3.4B
INR
Based on the financial report for Mar 31, 2025, Syncom Formulations (India) Ltd's Total Equity amounts to 3.4B INR.
What is Syncom Formulations (India) Ltd's Total Equity growth rate?
Total Equity CAGR 3Y
15%
Over the last year, the Total Equity growth was 19%. The average annual Total Equity growth rates for Syncom Formulations (India) Ltd have been 15% over the past three years .
